Sort
30,917 grants matching “tumor microenvironment”
Extracellular Proteins as Signals in Endothelial Growth
$375,150E Helene Sage · Benaroya Research Inst At Virginia Mason · R01 · FY2007 · GM
Regulation of Pancreatic Oncogenesis by the Gut Microbiome
$375,150Diane M Simeone · New York University School Of Medicine · R01 · FY2021 · CA
Control of regulatory T cells by IL-17 in colorectal cancer
$375,150Kepeng Wang · University Of Connecticut Sch Of Med/Dnt · R01 · FY2025 · CA
Extracellular Proteins as Signals in Endothelial Growth
$375,150E Helene Sage · Benaroya Research Inst At Virginia Mason · R01 · FY2009 · GM
Regulation of Pancreatic Oncogenesis by the Gut Microbiome
$375,150George Miller · New York University School Of Medicine · R01 · FY2018 · CA
Investigating the Role of Emergent Oscillations of Hypoxia Inducible Factor-1 alpha Activity in Cancer Growth and Progression
$375,150Fnu Kshitiz · University Of Connecticut Sch Of Med/Dnt · R37 · FY2020 · CA
Antigen-independent prediction and biomarker identification of cancer-specific T cells
$375,150Bo Li · Ut Southwestern Medical Center · R01 · FY2022 · CA
Regulation of Pancreatic Oncogenesis by the Gut Microbiome
$375,150Diane M Simeone · New York University School Of Medicine · R01 · FY2020 · CA
Investigating the Role of Emergent Oscillations of Hypoxia Inducible Factor-1 alpha Activity in Cancer Growth and Progression
$375,150Fnu Kshitiz · University Of Connecticut Sch Of Med/Dnt · R37 · FY2021 · CA
The sperm specific protein, COX6B2, promotes metabolic reprogramming in lung adenocarcinoma
$375,150Angelique Wright Whitehurst · Ut Southwestern Medical Center · R01 · FY2021 · CA
Control of regulatory T cells by IL-17 in colorectal cancer
$375,150Kepeng Wang · University Of Connecticut Sch Of Med/Dnt · R01 · FY2021 · CA
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy
$375,150Samuel Kent McBrayer · Ut Southwestern Medical Center · R01 · FY2025 · CA
Extracellular Proteins as Signals in Endothelial Growth
$375,150E Helene Sage · Benaroya Research Inst At Virginia Mason · R01 · FY2008 · GM
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy
$375,150Samuel Kent McBrayer · Ut Southwestern Medical Center · R01 · FY2022 · CA
Regulation of Pancreatic Oncogenesis by the Gut Microbiome
$375,150George Miller · New York University School Of Medicine · R01 · FY2017 · CA
Functional Consequences of Racially Associated Ephrin Alterations on the Prostate Tumor Microenvironment
$375,137Omar Franco Coronel · Endeavor Health Clinical Operations · R01 · FY2021 · CA
Elucidating the Role of Perivascular Niche in Glioblastoma Invasion and Therapeutic Resistance at Single Cell Resolution using Biomimetic Tumor Microenvironment Models
$375,134Mehdi Nikkhah · Arizona State University-Tempe Campus · R01 · FY2025 · NS
Reducing Off-Target Accumulation of Chemotherapeutic Nanomedicines
$375,134Thomas Anchordoquy · University Of Colorado Denver · R01 · FY2025 · CA
Functional Consequences of Racially Associated Ephrin Alterations on the Prostate Tumor Microenvironment
$375,127Omar Franco Coronel · Endeavor Health Clinical Operations · R01 · FY2020 · CA
Functional Consequences of Racially Associated Ephrin Alterations on the Prostate Tumor Microenvironment
$375,117Omar Franco Coronel · Endeavor Health Clinical Operations · R01 · FY2019 · CA
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$375,106Andrew E Aplin · Wistar Institute · P01 · FY2019 · CA
TBEL Administrative Core
$375,071Angelo Michael De Marzo · Johns Hopkins University · U54 · FY2024 · CA
Molecular Mechanism of miR-140 in Colon Cancer
$375,023Jingfang Ju · State University New York Stony Brook · R01 · FY2014 · CA
Bioreactor for Manufacturing Chemotactically Competent Immune Cell Therapies
$375,016Xiaohe Liu · Sri International · R61 · FY2024 · CA
Distinct contributions of mesenchymal cell niches in the therapeutic potential of the hedgehog pathway in triple negative breast cancer
$375,000Maribella Domenech · University Of Puerto Rico Mayaguez · SC1 · FY2023 · GM